Tesamorelin, an FDA-approved drug you may know as Egrifta, is one of the only GH peptides with actual FDA approval—and it earned that approval by proving it could reduce visceral abdominal fat (the dangerous deep belly fat wrapped around your organs) by 14-18% in clinical trials. What makes it different from just injecting growth hormone is that Tesamorelin stimulates your own pituitary gland to release GH in its natural pulsatile pattern, which means you're amplifying a system you already have rather than overriding it with exogenous hormone. The visceral fat reduction is where this compound really earns its reputation—this isn't subcutaneous fat that you can pinch, it's the metabolically active deep fat that drives insulin resistance, cardiovascular risk, and systemic inflammation, and reducing it delivers health benefits that go far beyond aesthetics. Clinical data also shows significant liver fat reduction (NAFLD improvement), improved triglycerides, and emerging evidence for cognitive benefits—likely driven by the sustained GH elevation improving brain metabolism and circulation. The daily injection commitment and the cost are real considerations, but for people specifically targeting visceral fat and wanting a compound with genuine clinical validation behind it, Tesamorelin is the gold standard.
Applications: Fat Loss, Metabolism Support, Growth Hormone
Written by Peppa at Peptide Upside — the peptide lifestyle guide. Research, calculate, and track your peptide journey.